E-mail

E-mail a Wiley Online Library Link

Rajni Sinha, Jonathan L. Kaufman, Hanna Jean Khoury Jr., Nassoma King, Pareen J. Shenoy, Carol Lewis, Kevin Bumpers, Amanda Hutchison-Rzepka, Mourad Tighiouart, Leonard T. Heffner, Mary Jo Lechowicz, Sagar Lonial and Christopher R. Flowers A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas Cancer 118

Version of Record online: 3 JAN 2012 | DOI: 10.1002/cncr.26660

In this phase 1 dose-escalation study of bortezomib with rituximab plus cyclophosphamide, doxorubicin, modified vincristine, and prednisone (R-CHOP) for patients with untreated follicular lymphoma and other indolent B-cell lymphomas, the results indicate that bortezomib at a maximum tolerated dose of 1.6 mg/m2 in combination with modified R-CHOP does not add to the toxicity of the regimen.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH